Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.43|
|52 Week High||US$3.34|
|52 Week Low||US$17.99|
|1 Month Change||-14.89%|
|3 Month Change||-23.61%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-77.13%|
Recent News & Updates
Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Galecto EPS misses by $0.07
Galecto (GLTO): Q1 GAAP EPS of -$0.53 misses by $0.07.Cash, cash equivalents, and investments as of March 31, 2021 were approximately $149M.Press Release
|GLTO||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how GLTO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GLTO performed against the US Market.
Stable Share Price: GLTO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: GLTO's weekly volatility has decreased from 12% to 5% over the past year.
About the Company
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis.
Galecto Fundamentals Summary
|GLTO fundamental statistics|
Is GLTO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GLTO income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.93|
|Net Profit Margin||0.00%|
How did GLTO perform over the long term?See historical performance and comparison
Is Galecto undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GLTO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GLTO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GLTO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: GLTO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GLTO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GLTO is good value based on its PB Ratio (0.6x) compared to the US Biotechs industry average (2.9x).
How is Galecto forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GLTO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GLTO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GLTO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GLTO is forecast to have no revenue next year.
High Growth Revenue: GLTO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GLTO is forecast to be unprofitable in 3 years.
How has Galecto performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: GLTO is currently unprofitable.
Growing Profit Margin: GLTO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GLTO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GLTO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLTO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: GLTO has a negative Return on Equity (-34.56%), as it is currently unprofitable.
How is Galecto's financial position?
Financial Position Analysis
Short Term Liabilities: GLTO's short term assets ($107.7M) exceed its short term liabilities ($4.8M).
Long Term Liabilities: GLTO's short term assets ($107.7M) exceed its long term liabilities ($635.0K).
Debt to Equity History and Analysis
Debt Level: GLTO is debt free.
Reducing Debt: GLTO had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GLTO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GLTO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 48.3% each year.
What is Galecto current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GLTO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GLTO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GLTO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GLTO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GLTO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hans Schambye (55 yo)
Dr. Hans T. Schambye, MD, Ph D, serves as Member of Board of Directors at BioInnovation Institute. Dr. Schambye is Co-Founder and has been Chief Executive Officer at Galecto, Inc. since 2020 and serves as...
CEO Compensation Analysis
Compensation vs Market: Hans's total compensation ($USD3.90M) is above average for companies of similar size in the US market ($USD545.22K).
Compensation vs Earnings: Hans's compensation has increased whilst the company is unprofitable.
Experienced Management: GLTO's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: GLTO's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GLTO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: GLTO only recently listed within the past 12 months.
Galecto, Inc.'s employee growth, exchange listings and data sources
- Name: Galecto, Inc.
- Ticker: GLTO
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$86.648m
- Shares outstanding: 25.26m
- Website: https://galecto.com
Number of Employees
- Galecto, Inc.
- 75 State Street
- Suite 100
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 23:49|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.